FDA grants accelerated approval for Jemperli in endometrial cancer – GSK
The FDA has granted accelerated approval to Jemperli (dostarlimab), from GlaxoSmithKline, for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment… read more.